EGM
KLRS

Engineers Gate Manager’s Kalaris Therapeutics KLRS Stock Holding History

Engineers Gate Manager’s Portfolio KLRS Stock Details KLRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-701
Closed -$6.77K – 2666
2024
Q4 		$6.77K Buy
701
+245
+54% +$3.71K ﹤0.01% 2175
2024
Q3 		$8.47K Sell
456
-245
-35% -$4.29K ﹤0.01% 2061
2024
Q2 		$11.7K Hold
701
– – ﹤0.01% 1868
2024
Q1 		$12.2K Sell
701
-2,027
-74% -$33.1K ﹤0.01% 1854
2023
Q4 		$42.7K Buy
+2,728
New +$108K ﹤0.01% 1859

Other funds holding KLRS

SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
GS
Gilead Sciences Foster City, California $2.12B AUM 143.53% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Engineers Gate Manager's KLRS Position: Q1 2025 in Review

Engineers Gate Manager sold out of Kalaris Therapeutics (KLRS) in Q1 2025, closing a stake of 701 shares — an estimated $6.77K sold.

Engineers Gate Manager first reported a position in KLRS in Q4 2023 and held it in 5 quarters. The position peaked at $42.7K in Q4 2023. 32 funds tracked by Wall St. Rank hold KLRS as of Q1 2025.

  • Engineers Gate Manager reported no remaining Kalaris Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Engineers Gate Manager sold 701 Kalaris Therapeutics shares in Q1 2025, an estimated $6.77K.
  • Engineers Gate Manager first reported a position in Kalaris Therapeutics in Q4 2023 and held it in 5 quarters.
  • Engineers Gate Manager's Kalaris Therapeutics position peaked at $42.7K in Q4 2023.
  • 32 funds tracked by Wall St. Rank held Kalaris Therapeutics as of Q1 2025.

Based on Engineers Gate Manager's 13F filing for Q1 2025, filed 15 May 2025.